Moreover, genome-wide screening platform identified PVT1 could regulate gemcitabine sensitivity in pancreatic cancer cells ASPC1, down-regulation of PVT1 sensitize tumor cells to gemcitabine [41], these results implied that PVT1 and HAR1A may be explored as potential biomarkers for indicating therapeutic efficiency of cancer patients. The gene discussed is PVT1; the disease is familial pancreatic carcinoma.